{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:09:04Z","timestamp":1791216544199,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Orion Corporation Orion Pharma"},{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s13318-019-00577-5","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T19:21:15Z","timestamp":1569871275000},"page":"747-759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Drug\u2013Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0881-846X","authenticated-orcid":false,"given":"Christian","family":"Zurth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Koskinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Prien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Korjamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Graudenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Denner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Bairlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens-Jeremias","family":"von B\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hille","family":"Gieschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"issue":"5","key":"577_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.clgc.2018.07.017","volume":"16","author":"K Fizazi","year":"2018","unstructured":"Fizazi K, Smith MR, Tombal B. Clinical development of darolutamide: a novel androgen receptor antagonist for the treatment of prostate cancer. Clin Genitourin Cancer. 2018;16(5):332\u201340. \n                    https:\/\/doi.org\/10.1016\/j.clgc.2018.07.017\n                    \n                  .","journal-title":"Clin Genitourin Cancer."},{"key":"577_CR2","unstructured":"US Food and Drug Administration. FDA approves darolutamide for non-metastatic castration-resistant prostate cancer. 2019. \n                    https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer\n                    \n                  . Accessed 31 July 2019."},{"key":"577_CR3","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Nubeqa (darolutamide) US prescribing information. 2019. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212099Orig1s000lbl.pdf\n                    \n                  . Accessed 31 July 2019."},{"issue":"9","key":"577_CR4","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/s1470-2045(14)70240-2","volume":"15","author":"K Fizazi","year":"2014","unstructured":"Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15(9):975\u201385. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(14)70240-2\n                    \n                  .","journal-title":"Lancet Oncol."},{"issue":"5","key":"577_CR5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2015.09.046","volume":"69","author":"C Massard","year":"2016","unstructured":"Massard C, Penttinen HM, Vjaters E, Bono P, Lietuvietis V, Tammela TL, et al. Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol. 2016;69(5):834\u201340. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2015.09.046\n                    \n                  .","journal-title":"Eur Urol"},{"issue":"13","key":"577_CR6","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235\u201346. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1815671\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"577_CR7","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1038\/srep12007","volume":"5","author":"AM Moilanen","year":"2015","unstructured":"Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007. \n                    https:\/\/doi.org\/10.1038\/srep12007\n                    \n                  .","journal-title":"Sci Rep."},{"key":"577_CR8","doi-asserted-by":"crossref","unstructured":"Sandmann S, Trummel D, Seidel D, Nubbemeyer R, Gieschen H, Zurth C. Higher blood-brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography. In: ASCO genitourinary cancers symposium; 14\u201316 February; San Francisco 2019. Abstract 156.","DOI":"10.1200\/JCO.2019.37.7_suppl.156"},{"issue":"6_suppl","key":"577_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1200\/JCO.2018.36.6_suppl.345","volume":"36","author":"C Zurth","year":"2018","unstructured":"Zurth C, Sandmann S, Trummel D, Seidel D, Gieschen H. Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography. J Clin Oncol. 2018;36(6_suppl):345.","journal-title":"J Clin Oncol."},{"issue":"1","key":"577_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/bcp.13425","volume":"84","author":"GE Benoist","year":"2018","unstructured":"Benoist GE, van Oort IM, Smeenk S, Javad A, Somford DM, Burger DM, et al. Drug\u2013drug interaction potential in men treated with enzalutamide: mind the gap. Br J Clin Pharmacol. 2018;84(1):122\u20139. \n                    https:\/\/doi.org\/10.1111\/bcp.13425\n                    \n                  .","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"577_CR11","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1124\/dmd.115.069096","volume":"44","author":"T Bohnert","year":"2016","unstructured":"Bohnert T, Patel A, Templeton I, Chen Y, Lu C, Lai G, et al. Evaluation of a new molecular entity as a victim of metabolic drug\u2013drug interactions\u2014an industry perspective. Drug Metab Dispos. 2016;44(8):1399\u2013423. \n                    https:\/\/doi.org\/10.1124\/dmd.115.069096\n                    \n                  .","journal-title":"Drug Metab Dispos"},{"key":"577_CR12","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions. 2012. \n                    https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions_en.pdf\n                    \n                  . Accessed 20 May 2019."},{"key":"577_CR13","unstructured":"US Food and Drug Administration. Clinical drug interaction studies\u2014study design, data analysis, and clinical implications. Guidance for industry [draft guidance]. 2017. \n                    https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-study-design-data-analysis-and-clinical-implications-guidance\n                    \n                  . Accessed 20 May 2019."},{"key":"577_CR14","unstructured":"US Food and Drug Administration. In vitro metabolism and transporter-mediated drug-drug interaction studies. Guidance for industry [draft guidance]. 2017. \n                    https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/vitro-metabolism-and-transporter-mediated-drug-drug-interaction-studies-guidance-industry\n                    \n                  . Accessed 16 Aug 2019."},{"issue":"4","key":"577_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/cpt.525","volume":"101","author":"T Prueksaritanont","year":"2017","unstructured":"Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, et al. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther. 2017;101(4):519\u201330. \n                    https:\/\/doi.org\/10.1002\/cpt.525\n                    \n                  .","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"577_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/cpt.973","volume":"104","author":"CC McLean","year":"2018","unstructured":"McLean CC, Teft WA, Morse BL, Gryn SE, Hegele RA, Kim RB. Food effect on rosuvastatin disposition and low-density lipoprotein cholesterol. Clin Pharmacol Ther. 2018;104(3):525\u201333. \n                    https:\/\/doi.org\/10.1002\/cpt.973\n                    \n                  .","journal-title":"Clin Pharmacol Ther"},{"key":"577_CR17","doi-asserted-by":"publisher","first-page":"291704","DOI":"10.1155\/2012\/291704","volume":"2012","author":"H Li","year":"2012","unstructured":"Li H, Hodgson E, Watson L, Shukla A, Nelson JJ. Comorbidities and concomitant medication use in men with prostate cancer or high levels of PSA compared to matched controls: a GPRD analysis. J Cancer Epidemiol. 2012;2012:291704. \n                    https:\/\/doi.org\/10.1155\/2012\/291704\n                    \n                  .","journal-title":"J Cancer Epidemiol."},{"key":"577_CR18","doi-asserted-by":"publisher","first-page":"291704","DOI":"10.1155\/2012\/291704","volume":"2012","author":"N Shore","year":"2019","unstructured":"Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, et al. Evaluation of clinically relevant drug\u2013drug interactions with darolutamide in the phase 3 ARAMIS trial for patients with nonmetastatic castration-resistant prostate cancer.\u00a0Targ Oncol. 2019. \n                    https:\/\/doi.org\/10.1007\/s11523-019-00674-0\n                    \n                  .","journal-title":"J Cancer Epidemiol."},{"issue":"8","key":"577_CR19","doi-asserted-by":"publisher","first-page":"904","DOI":"10.6004\/jnccn.2010.0067","volume":"8","author":"AM Berger","year":"2010","unstructured":"Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, et al. NCCN clinical practice guidelines cancer-related fatigue. J Natl Compr Cancer Netw. 2010;8(8):904\u201331.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"577_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1046\/j.1365-2125.1998.00034.x","volume":"46","author":"KT Kivisto","year":"1998","unstructured":"Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol. 1998;46(1):49\u201353. \n                    https:\/\/doi.org\/10.1046\/j.1365-2125.1998.00034.x\n                    \n                  .","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"577_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/00000539-199603000-00015","volume":"82","author":"KT Olkkola","year":"1996","unstructured":"Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996;82(3):511\u20136. \n                    https:\/\/doi.org\/10.1097\/00000539-199603000-00015\n                    \n                  .","journal-title":"Anesth Analg"},{"key":"577_CR22","unstructured":"US Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. 2017. \n                    https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers\n                    \n                  . Accessed 15 Aug 2019."},{"key":"577_CR23","volume-title":"Top 100 drug interactions 2018. A guide to patient management","author":"PD Hansten","year":"2018","unstructured":"Hansten PD, Horn JR. Top 100 drug interactions 2018. A guide to patient management. 19th ed. Dunnellon: H&H Publications, LLP; 2018.","edition":"19"},{"key":"577_CR24","doi-asserted-by":"crossref","unstructured":"Zurth C, Graudenz K, Denner K, Vairlein M, Korjamo T, Fricke R, et al. Drug\u2013drug interaction of darolutamide with cytochrome P450 and P-glycoprotein substrates: results from clinical and in vitro studies. In: ASCO genitourinary cancers symposium, San Francisco. 2019.","DOI":"10.1200\/JCO.2019.37.7_suppl.297"},{"key":"577_CR25","unstructured":"Astellas Pharma US Inc. PROGRAF (tacrolimus) US Prescribing Information. 2018. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/050708s050,050709s042,210115s002lbl.pdf\n                    \n                  . Accessed 6 Sept 2019."},{"issue":"10","key":"577_CR26","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/S0149-2918(03)80316-8","volume":"25","author":"PD Martin","year":"2003","unstructured":"Martin PD, Warwick MJ, Dane AL, Brindley C, Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther. 2003;25(10):2553\u201363.","journal-title":"Clin Ther"},{"issue":"3","key":"577_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bcp.12377","volume":"78","author":"T Prueksaritanont","year":"2014","unstructured":"Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, et al. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin Pharmacol. 2014;78(3):587\u201398. \n                    https:\/\/doi.org\/10.1111\/bcp.12377\n                    \n                  .","journal-title":"Br J Clin Pharmacol"},{"key":"577_CR28","doi-asserted-by":"crossref","unstructured":"Zurth C, Fizazi K, Fricke R, Gieschen H, Graudenz K, Koskinen M, et al. Assessing the clinical relevance of drug\u2013drug interactions (DDI) with darolutamide (DARO). ESMO Congress; 27 September\u20131 October; Barcelona, Spain. 2019.","DOI":"10.1093\/annonc\/mdz248.047"},{"key":"577_CR29","unstructured":"Astellas Pharma US Inc. Xtandi (enzalutamide) US prescribing information. 2018. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203415s014lbl.pdf\n                    \n                  . Accessed 11 June 2019."},{"issue":"2","key":"577_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.eururo.2018.09.011","volume":"75","author":"GE Benoist","year":"2019","unstructured":"Benoist GE, van Oort IM, Burger DM, Koch BCP, Mehra N, van Erp NP. The combination of enzalutamide and opioids: a painful pitfall? Eur Urol. 2019;75(2):351\u20132. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2018.09.011\n                    \n                  .","journal-title":"Eur Urol"},{"key":"577_CR31","unstructured":"Janssen Ortho LLC. Erleada (apalutamide) US prescribing information. 2018. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210951s000lbl.pdf\n                    \n                  . Accessed 22 July 2019."},{"issue":"10","key":"577_CR32","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","volume":"54","author":"JA Gibbons","year":"2015","unstructured":"Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057\u201369. \n                    https:\/\/doi.org\/10.1007\/s40262-015-0283-1\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"key":"577_CR33","unstructured":"US Center for Drug Evaluation and Research. NDA\/BLA clinical pharmacology and biopharmaceutics review NDA 203415 Xtandi (enzalutamide). 2012. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203415Orig1s000ClinPharmR.pdf\n                    \n                  . Accessed 26 Sept 2018."},{"key":"577_CR34","unstructured":"US Center for Drug Evaluation and Research. NDA\/BLA multi-disciplinary review and evaluation NDA 210951 Erleada (apalutamide). 2018. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210951Orig1s000MultidisciplineR.pdf\n                    \n                  . Accessed 26 Sept 2018."},{"issue":"6","key":"577_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M15-0288","volume":"163","author":"WP Battisti","year":"2015","unstructured":"Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med.\u00a02015;163(6):461\u20134.\u00a0\n                    https:\/\/doi.org\/10.7326\/M15-0288\n                    \n                  .","journal-title":"Ann Intern Med"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-019-00577-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-019-00577-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-019-00577-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T19:24:38Z","timestamp":1601321078000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-019-00577-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["577"],"URL":"https:\/\/doi.org\/10.1007\/s13318-019-00577-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]},"assertion":[{"value":"30 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This trial was supported by Orion Corporation Orion Pharma and Bayer AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Christian Zurth, Robert Fricke, Olaf Prien, Kristina Graudenz, Karsten Denner, Michaela Bairlein, Clemens-Jeremias von B\u00fchler, Gary Wilkinson and Hille Gieschen are employees of Bayer AG. Drs. Zurth, Prien, Denner, Wilkinson and Gieschen are also stockholders of Bayer AG. Mikko Koskinen and Timo Korjamo are employees and stockholders of Orion Corporation Orion Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The protocols were approved by the Ethics Committee of the State Medical Chamber of Berlin (NCT03048110 and NCT02671097) and the Ethics Committee of the State Medical Chamber of Baden-W\u00fcrttemberg (NCT03237416).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants in the studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Availability of the data underlying this publication will be determined according to Bayer\u2019s commitment to the EFPIA\/PhRMA \u201cPrinciples for responsible clinical trial data sharing.\u201d This pertains to the scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified scientific and medical researchers patient-level clinical trial data, study-level clinical trial data and protocols from clinical trials in patients for medicines and indications approved in the United States (US) and European Union (EU) as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 1, 2014. Interested researchers can use\n                      \n                      to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study Sponsors section of the portal. Data access will be granted to anonymized patient-level data, protocols and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that patient privacy is safeguarded.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}}]}}